To our knowledge, this study is the first with real-world data that evaluate the effects of SGLT-2 inhibitors on body composition and fluid status measured by a BIA device in patients with coronary artery disease and heart failure participating in a CR program. The gene discussed is SLC5A2; the disease is coronary artery disorder.